

# The use of total funds channelled through “la Caixa” to Gavi programmes in 2019

Final Report to the “la Caixa” Foundation  
(for Gavi)  
June 2020



# Executive summary

---

The “la Caixa” Foundation and GAVI partnership is aimed at protecting the lives of the world’s most disadvantaged children, with a specific focus on providing life-saving protection against pneumonia by funding pneumococcal vaccine. In 2019 this partnership has contributed funds to vaccinate an estimated 850,139 children with pneumococcal vaccine in Mozambique.

Thanks to the generosity of the “la Caixa” Foundation, “la Caixa” employees, the Business Alliance for Child Vaccinations, and microdonations from the Spanish public, The Bill and Melinda Gates Foundation have matched your funds to thus double the impact.

In total, “la Caixa” Foundation has thus channelled USD 8,709,712 to Gavi in 2019.

# Table of content

---

- 1. Overview of use of “la Caixa” funds in 2019**
- 2. Background information on Pneumonia and Mozambique**
- 3. Gavi Matching Fund report**

# 1

## Overview of the use of 2019 funds

# 2019 Contributions and impact

## “la Caixa” 2019 Contributions:

- “la Caixa” Foundation:
  - EUR 2,000,000
  - USD 2,172,140
- Business Alliance:
  - EUR 1,878,123
  - USD 2,047,154
- Employees & Microdonations:
  - EUR 128,045
  - USD 135,561

### Total:

- **EUR 4,006,168**
- **USD 4,354,856**

The Gavi Matching Fund doubled your contributions with ≈ \$ 4,354,856\*\* from the Bill and Melinda Gates Foundation



## Projected Impact:

- **2,916,058 doses\* of pneumococcal vaccine were purchased**
- **Approximately 850,139 children immunized\*\*\***

*Note: All impact calculations are estimates.*

*\*total includes possible indicative number of doses purchased with funds from the Gavi Matching Fund*

*\*\*All Gavi Matching Fund contributions are recorded in US dollars*

*\*\*\* This number acknowledges a 10% wastage*

# Detailed breakdown of la Caixa Funds for pneumococcal vaccines and impact

Use of funds and impact in Mozambique				Total La Caixa
	“la Caixa” Foundation	Employees & Microdonations	Business Alliance	Investment amount
Funds (USD)	<b>EUR 2,000,000 **</b> <b>USD 2,172,140</b>	<b>EUR 128,045**</b> <b>USD 135,561.24</b>	<b>EUR 1,878,123**</b> <b>USD 2,047,154</b>	<b>EUR 4,006,128**</b> <b>USD 4,354,856</b>
Doses purchased*	727,244*	45,386*	685,398*	1,458,028*
Children immunized	212,019	13,232	199,819	425,142
Funds (%)	50%	3.2%	46.8%	100%

\*These numbers include the 10% wastage. Total includes possible indicative number of doses purchased with La Caixa Funds (only)

\*\* These figures are reported by la Caixa and not validated by Gavi.

Note: All impact calculations are estimates. Adjustments from the preliminary report, as well as an increase in funds disbursed vs. funds received, reflect currency adjustments, interest earned, and fluctuations in the global weighted average cost of vaccines.

The prices shared for each vaccine is the Weighted Average Price. We use the WAP as we have multiple presentations of each vaccine and a mix of the presentations is bought by Gavi programs each year. In this case, the \$ 2.99 represents a WAP for PCV based off the 2019 UNICEF price list and weighted in proportion to volumes of each presentation procured the previous year.

# Detailed breakdown of funds matched by the Bill & Melinda Gates Foundation (Matching Fund)

Year	Funding Source	Country	Vaccine	Funds Matched (%)	Funds Matched (USD)	Doses Purchased	Children Immunized
<b>2019</b>	<b>Total “la Caixa” Investment</b>	<b>Mozambique</b>	<b>Pneumococcal</b>	<b>100%</b>	<b>USD 8,709,712</b>	<b>2,916,056*</b>	<b>850,139</b>
2019	“la Caixa” Foundation	Mozambique	Pneumococcal	100%	USD 2,172,140	727,244*	212,019
2019	Employees and Microdonations	Mozambique	Pneumococcal	100%	USD 135,561.24	45,386*	13,232
2019	Business Alliance	Mozambique	Pneumococcal	100%	USD 2,047,154	685,398*	199,819

\*These numbers include the 10% wastage

Note: These numbers include the 10% wastage. Total includes possible indicative number of doses with La Caixa Funds (only). These figures are reported by la Caixa and not validated by Gavi.

7 The prices shared for each vaccine is the Weighted Average Price. We use the WAP as we have multiple presentations of each vaccine and a mix of the presentations is bought by Gavi programs each year. In this case, the \$ 2.99 represents a WAP for PCV based off the 2019 UNICEF price list and weighted in proportion to volumes of each presentation procured the previous year.

# Use of “la Caixa” Foundation funds corresponding to the contributions in 2019 1/2



## FINANCIAL STATEMENT ON FUNDS UTILIZATION

### LA CAIXA FUNDS

Details of contributions received, funds allocated to Gavi programmes, and the balance of contribution

Table 1: 2019 Contributions received as of 31 March 2020

Description or reference	Date of contributions received by Gavi	Amount of contribution received in US\$
2019 Funding from La Caixa Foundation (Equivalent to EUR 1,000,000)	14 November 2019	1,095,600
2019 Funding from Business Alliance for Childhood Vaccination, Employees' Donations and/or Public Microdonations Campaign	14 February 2020	2,047,154
2019 Funding from Business Alliance for Childhood Vaccination, Employees' Donations and/or Public Microdonations Campaign	20 February 2020	1,212,102
Total 2019 contributions received as of 31 March 2020		4,354,856



# Use of “la Caixa” Foundation funds corresponding to the contributions in 2019 2/2

Table 2: Funds allocated to Gavi programmes as of 31 March 2020

Programme description	Implementing country	Number of doses of vaccines	Date of fund allocations	Amount of funds allocated in US\$	
Pneumococcal Programmes (CTN 2019-443)	Mozambique		11 February 2019	886,742	Note 1
Pneumococcal Programmes (CTN 2019-495)	Mozambique		06 May 2019	1,571,240	
Pneumococcal Programmes (CTN 2020-411)	Mozambique		15 November 2019	635,170	
<b>Total funds allocated to Gavi programmes as of 31 March 2020</b>		<b>1,066,604</b>		<b>3,093,152</b>	

Table 3: Balance of contribution as of 31 March 2020

Description	Amount in US\$	
Total contributions received, per Table 1 above	4,354,856	
Total funds allocated to Gavi programmes, per Table 2 above	(3,093,152)	
<b>Balance of 2019 contribution as of 31 March 2020</b>	<b>1,261,704</b>	Note 2

## Notes:

1. US\$ 1,693,090 of the Pneumococcal Programme for Mozambique in this CTN was sponsored by La Caixa. Of this total, US\$ 806,347 was covered by La Caixa's 2018 funding, and was, therefore, reported as allocated in the previous Financial Statement on Funds Utilization as of 28 February 2019. The remaining US\$ 886,742 was covered by La Caixa's 2019 funding, and was, therefore, reported as allocated in this present Financial Statement on Funds Utilization.
2. This represents funding still to be spent on relevant Gavi programmes.

# The total contributions for 2019 are EUR 2,006,168

---

## **Business Alliance: EUR 1,878,123**

*818 companies – EUR 1,162,020*

*2,660 Private Banking donations – EUR 716,103*

## **Employees & Microdonations: EUR 128,045**

*754 employees – EUR 43,756*

*50,821 microdonations – EUR 84,289*

# 2

## Background information on pneumonia and recipient country

# The challenge: pneumonia and pneumococcal vaccine

---

*Streptococcus pneumoniae*, commonly known as pneumococcal disease, is the leading cause of pneumonia – the world's number one killer of children under five years of age.

According to UNICEF\*, Pneumonia kills more children than any other infectious disease, claiming the lives of over 800,000 children under five every year, or around 2,200 every day. This includes over 153,000 newborns. Progress in reducing deaths due to pneumonia in children under five has been significantly slower than for other infectious diseases. Since 2000, under-five deaths due to pneumonia have declined by 54 per cent, while deaths due to diarrhoea have decreased by 64 per cent and are now almost half of pneumonia deaths.

The most effective way to prevent these deaths is to ensure that all children have access to safe, affordable vaccines.

To accelerate the development and production of a new generation of pneumococcal vaccines, more targeted at the needs of developing countries and more affordable, GAVI, the World Bank and donors launched the pneumococcal Advance Market Commitment (AMC) in 2009.


GAVI countries rolling out pneumococcal vaccines will potentially avert more than 700,000 future deaths between 2021 and 2025\*\*.

\*UNICEF Data, November 2019: <https://data.unicef.org/topic/child-health/pneumonia/>

\*\* Gavi prospectus: The 2021-2025 Gavi, the Vaccine Alliance Investment Opportunity, 2019.

# The challenge: pneumonia and pneumococcal vaccine

## Deaths of children under five by infectious disease, 2000 vs 2018



**Source:** UNICEF analysis based on WHO and Maternal and Child Epidemiology Estimation Group interim estimates produced in September 2019, applying cause of deaths for the year 2017 to United Nations Inter-agency Group for Child Mortality Estimation estimates for the year 2018.

# Country Profile: Mozambique

## Mozambique




Total population (2019)	31,156,700
Birth cohort (2019)	1,161,076
Surviving Infants (surviving to 1 year per year, 2019)	1,073,337
Infant mortality rate (deaths < 1 year per 1000 births, 2015)	57/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015)	79/1000
World Bank Index, IDA (2015)	3.48
Gross Nation Income (per capita US\$, 2015)	590
No. of districts/territories (2018)	161

# Country Profile: Mozambique

## DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2018)	N/A
DTP3 - Official country estimates (2018)	90%
M:F sex ratio at birth (2019)	1.03
Household survey: DTP3 coverage for male (2010)	76.20%
Household survey: DTP3 coverage for female (2010)	76.10%
Household survey: Last DTP3 survey (2010)	76%
% districts achieving > 80% DTP3 coverage (2018)	96%
% districts achieving < 50% DTP3 coverage (2018)	0%
MCV WHO/UNICEF estimates (2018)	85%
WUENIC Data PCV3 coverage (2019)	90%

# Country Profile: Mozambique





# 3

## Gavi Matching Fund Report

**Use of the Bill & Melinda Gates  
Foundation Matching Fund funds  
corresponding to the contributions  
channelled through “la Caixa” in 2019**

# Use of Bill & Melinda Gates Foundation Matching Fund funds corresponding to the contributions channelled through “la Caixa” in 2019 1/2



## FINANCIAL STATEMENT ON FUNDS UTILIZATION

### GATES MATCHING FUNDS FOR LA CAIXA - 2019 CONTRIBUTION

Details of contributions matched, funds allocated to Gavi programmes, and the balance of contributions matched

Table 1: 2019 Contributions matched by the Gates Matching Fund as of 31 March 2020

Description or reference	Amount of contribution matched in US\$
Gates Matching Funds for 2019 Funding from La Caixa Foundation	1,095,600
Gates Matching Funds for 2019 Funding from La Caixa Business Alliance for Childhood Vaccination, Employees' Donations and/or Public Microdonations Campaign	1,266,602
Gates Matching Funds for 2019 Funding from La Caixa Business Alliance for Childhood Vaccination, Employees' Donations and/or Public Microdonations Campaign	780,552
Gates Matching Funds for 2019 Funding from La Caixa Business Alliance for Childhood Vaccination, Employees' Donations and/or Public Microdonations Campaign	135,561
Gates Matching Funds for 2019 Funding from La Caixa Business Alliance for Childhood Vaccination, Employees' Donations and/or Public Microdonations Campaign	1,076,541
<b>Total 2019 contributions matched by the Gates Matching Fund as of 31 March 2020</b>	<b>4,354,856</b>

# Use of Bill & Melinda Gates Foundation Matching Fund funds corresponding to the contributions channelled through “la Caixa” in 2019 2/2

Table 2: Funds allocated to Gavi programmes as of 31 March 2020

Programme description	Implementing country	Date of fund allocations	Amount of funds allocated in US\$	
Pneumococcal Programmes (CTN 2019-443)	Mozambique	11 February 2019	886,740	Note 1
Pneumococcal Programmes (CTN 2019-488)	Mozambique	25 March 2019	(57,720)	Note 2
Pneumococcal Programmes (CTN 2019-495)	Mozambique	06 May 2019	1,571,240	
Pneumococcal Programmes (CTN 2018-761)	Mozambique	08 August 2019	(37,599)	Note 2
Pneumococcal Programmes (CTN 2020-411)	Mozambique	15 November 2019	730,490	
Total funds allocated to Gavi programmes as of 31 March 2020			3,093,152	

Table 3: Balance of contributions matched as of 31 March 2020

Description	Amount in US\$	
Total contributions matched by the Gates Matching Fund, per Table 1 above	4,354,856	
Total funds allocated to Gavi programmes, per Table 2 above	(3,093,152)	
Balance of contributions matched as of 31 March 2020	1,261,705	Note 3

## Notes:

- US\$ 1,693,090 of the Pneumococcal Programme for Mozambique in this CTN was sponsored by the Gates Matching Funds. Of this total, US\$ 806,350 was covered by the Gates Matching Funds for La Caixa's 2018 contributions, and was, therefore, reported as allocated in the previous Financial Statement on Funds Utilization as of 28 Feb 2019. The remaining US\$ 886,740 was covered by the Gates Matching Funds for La Caixa's 2019 contributions, and was, therefore, reported as allocated in this Financial Statement on Funds Utilization.
- These negative amounts represent a return of funds from GAVI's procurement agent, UNICEF, due to actual costs (e.g., of freight, vaccine, devices) being lower than originally estimated in CTNs. Returned funds are subsequently re-spent on other programmes.
- This represents funding still to be spent on relevant Gavi programmes.  
*The previous Financial Statement dated 28 Feb 2019 showed programmes amounting to US\$ 3,416,524 spent in advance of being funded by the Gates Matching Fund. Gavi received the Matching Funds to cover this advanced expenditure on 7 Jun 2019.*

**Thank You!**

---

